Thursday, Jul 8, 1999
South San Francisco, Calif. -- July 8, 1999 --At Genentech's request, the underwriters of Roche's upcoming public offering of Genentech Common Stock have reserved shares for sale to former non-institutional Genentech shareholders who are interested in purchasing shares in the offering. This unique program is being offered in response to requests by former non-institutional Genentech shareholders to have the opportunity to participate in the public offering.
This unique arrangement provides for a limited number of shares of Genentech Common Stock to be reserved for purchase by Genentech's former non-institutional shareholders who held shares in the company as of June 16, 1999. The offering price will be equal to the initial offering price to the public, which is currently anticipated to be between $85 and $95 per share, but could be higher or lower than this range. The purchase requirement available to former non-institutional shareholders is a minimum of 50 shares with a maximum allowable purchase of 200 shares. The availability of shares will be based on, among other things, the level of demand, and the underwriters may direct anywhere from zero to the full number of shares requested. Former non-institutional Genentech shareholders should contact Genentech for further information at (650) 225-1260. The deadline for indication of interest is July 12, 1999. A written prospectus describing the shares may be obtained from Genentech.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) but has not yet become effective. This is expected to occur during the week of July 19, 1999.
This notice does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufacturers and markets human pharmaceuticals for significant unmet medical needs. Twelve of the approved products of biotechnology stem from Genentech science, seven of which Genentech markets directly in the United States. The company has headquarters in South San Francisco, California.
# # #